ABBV vs. ALGN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ABBV and ALGN, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ABBV dominates in value with a market cap of 321.13 billion USD, eclipsing ALGN’s 12.46 billion USD by roughly 25.77×.
ALGN carries a higher beta at 1.68, indicating it’s more sensitive to market moves, while ABBV remains steadier at 0.55.
| Symbol | ABBV | ALGN |
|---|---|---|
| Company Name | AbbVie Inc. | Align Technology, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Devices |
| CEO | Mr. Robert A. Michael CPA | Mr. Joseph M. Hogan |
| Price | 181.8 USD | 171.91 USD |
| Market Cap | 321.13 billion USD | 12.46 billion USD |
| Beta | 0.55 | 1.68 |
| Exchange | NYSE | NASDAQ |
| IPO Date | January 2, 2013 | January 30, 2001 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ABBV and ALGN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
For a detailed comparison of valuation metrics between ABBV and ALGN, please refer to the table below.
| Symbol | ABBV | ALGN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 76.62 | 30.88 |
| Forward PEG Ratio (TTM) | 7.16 | 2.92 |
| Price-to-Sales Ratio (P/S, TTM) | 5.60 | 3.13 |
| Price-to-Book Ratio (P/B, TTM) | 226.35 | 3.33 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 20.87 | 19.76 |
| EV-to-EBITDA (TTM) | 23.58 | 14.56 |
| EV-to-Sales (TTM) | 6.73 | 2.94 |
| EV-to-Free Cash Flow (TTM) | 25.08 | 18.56 |
Dividend Comparison
ABBV delivers a 3.51% dividend yield, blending income with growth, whereas ALGN appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.
| Symbol | ABBV | ALGN |
|---|---|---|
| Dividend Yield (TTM) | 3.51% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ABBV and ALGN, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ABBV’s current ratio of 0.76 signals a possible liquidity squeeze, while ALGN at 1.21 comfortably covers its short-term obligations.
- ABBV’s quick ratio of 0.64 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas ALGN at 1.08 maintains a comfortable buffer of liquid assets.
- ABBV is heavily leveraged (debt-to-equity ratio 49.22), which can boost returns but raises risk if borrowing costs climb, while ALGN at 0.03 keeps leverage at a more moderate level.
- ABBV (at 6.14) covers its interest payments, while ALGN shows “--” for minimal debt service.
| Symbol | ABBV | ALGN |
|---|---|---|
| Current Ratio (TTM) | 0.76 | 1.21 |
| Quick Ratio (TTM) | 0.64 | 1.08 |
| Debt-to-Equity Ratio (TTM) | 49.22 | 0.03 |
| Debt-to-Assets Ratio (TTM) | 0.51 | 0.02 |
| Interest Coverage Ratio (TTM) | 6.14 | -- |